Non-Oncology Biologics and Biosimilars Market Analysis Insights and Forecast for 2023-2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Non-Oncology Biologics and Biosimilars Market - (By Drug Category (Monoclonal Antibody, Enzyme Replacement Therapy, Toxins, Fusion Proteins, Vaccines, Insulin, Hormones, Gene Therapy, Cell Therapy, and Others), By Application Type (Cardiology, Dermatology, Hematology, Endocrinology, Neurology, Immunology, Respiratory, Rheumatology, Ophthalmology, and Others), By Product Type (Biologics and Biosimilars)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Non-Oncology Biologics and Biosimilars Market is expected to grow with a CAGR of 21.8% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2238

A biosimilar is a biological medicinal product that is highly similar to an already approved reference biologic. The safety, efficacy, and quality of biosimilars are rigorously evaluated in accordance with the pharmaceutical quality standards that govern all biologic medications. The growing demand for more accessible and effective treatments for various diseases has led to a surge in the global approval of biosimilars. In response, pharmaceutical companies are increasing the production of biosimilars, including oncology biosimilars and Remicade biosimilars, as part of their efforts to diversify revenue streams and meet the rising need for affordable healthcare. The global prevalence of chronic diseases continues to rise, driven by factors such as changing lifestyles and an ageing population, both of which contribute to the higher incidence of conditions like diabetes, hypertension, stroke, respiratory diseases, obesity, arthritis, and cancer. Notably, biosimilar monoclonal antibodies are becoming increasingly important in the treatment of cancer and rheumatoid arthritis.

List of Prominent Players in the Global Non-oncology Biologics and Biosimilars Market:
• AbbVie Inc.
• Sanofi
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Johnson & Johnson
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Takeda Pharmaceuticals
• BioMarin Pharmaceuticals
• GSK
• AstraZeneca
• Biogen
• Others

Market Dynamics:
Drivers-
The increasing demand for non-oncology biologics and biosimilars is driven by the growing prevalence of chronic non-oncology diseases, such as autoimmune disorders and Type 2 diabetes. This trend is fueling the expansion of the non-oncology biologics and biosimilars market. Advances in biotechnology and biopharmaceutical manufacturing processes have enabled the more efficient development and production of these biologics, thereby improving their accessibility and availability. Additionally, the high costs associated with non-oncology biologics have led to a growing demand for more affordable alternatives, such as biosimilars, which are becoming increasingly sought after by both healthcare providers and patients.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Challenges:
The primary challenges facing the global non-oncology biologics and biosimilars market include high costs, stringent regulations, a shortage of skilled professionals, and the absence of standardized protocols, particularly in emerging economies. These factors are expected to impede market growth. The drug distribution and development process remains costly, which could further slow market expansion. Additionally, the oncology biosimilars market will encounter challenges due to underdeveloped healthcare infrastructures and a lack of experienced personnel in developing regions. Regulatory barriers, clinical obstacles, and reluctance among manufacturers to invest in biologics are also expected to hinder progress. The COVID-19 pandemic disrupted supply chains and financial markets, negatively impacting businesses and exacerbating difficulties for generic drug producers, who supply a significant portion of the market. As a result, production may decrease, potentially leading to higher medication costs in the short term. However, innovative drug manufacturers are expected to fill the gap, thereby minimizing the overall impact on the market.

Regional Trends:
The North American non-oncology biologics and biosimilars market is expected to capture a significant share of the revenue, with strong growth projected in the near term. This growth is attributed to the presence of key market players and the rising cost of healthcare in the region. The increasing prevalence of cancer is also anticipated to drive market expansion. In Europe, the market holds a considerable share due to technological advancements, high levels of affluence, and supportive government programs. Additionally, increased healthcare investments and the presence of major market participants are contributing to rapid market growth in this region.

Recent Developments:
• In March 2023, Sandoz, a division of Novartis, has entered into a Memorandum of Understanding to build a new facility in Slovenia for the production of biologics. This action was intended to address the increasing worldwide need for biosimilar medications. The Sandoz investment was anticipated to be a minimum of USD 400 million, bolstering the company's aspiration to propel the future expansion of its worldwide biosimilars portfolio. This investment in Slovenia is one of the greatest ever made by the worldwide private sector.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2238

Segmentation of Global Non-Oncology Biologics and Biosimilars Market-
By Drug Category-
• Monoclonal Antibody
• Enzyme Replacement Therapy
• Toxins
• Fusion Proteins
• Vaccines
• Insulin
• Hormones
• Gene Therapy
• Cell Therapy
• Others
By Application Type-
• Cardiology
• Dermatology
• Hematology
• Endocrinology
• Neurology
• Immunology
• Respiratory
• Rheumatology
• Ophthalmology
• Others
By Product Type-
• Biologics
• Biosimilars
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/non-oncology-biologics-and-biosimilars-market/2238

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.